Loading...

APTOSE BIOSCIENCES INC Capital Structure Changes 8-K Filing

PTS

APTOSE BIOSCIENCES INC

()

2025 8-K

Financial Update

Press Release Issued

Press Release Notification

Shareholder Approvals

Management Agreement Update

Press Release Issued

Aptose Filing Update

Agreement Update

Press Release Issued

Press Release Issued

Acquisition Agreement

Press Release Issued

Financial Update

Press Release Issued

Press Release Issued

Regulatory Disclosure

Accounting Firm Change

Retention Awards Granted

Shareholder Meeting Results

Company Press Release

Press Release Notification

Press Release Issued

Investor Meetings

Contract Renewal

Regulation FD Disclosure

Debt-Equity Swaps

Investor Meetings

Financial Statements

Investor Meetings

Delisting Notice

Financial Results

Debt Conversion

Corporate Presentation

Press Release Issued

Equity Purchase Agreement

Sales Agreement

Stock Split Approval

Nasdaq Compliance

Corporate Presentation

Press Release Issued

Press Release Issued

Press Release Issued

Financial Results

Nasdaq Compliance Issue

Shareholder Meeting

Press Release Issued

Earnings Reports

Shareholder Meeting Results

Securities Purchase Agreement

Termination of Agreement

Results of Operations and F...

Amended Employment Agreements

Compliance with Nasdaq Rules

Results of Operations and F...

Regulation FD Disclosure

Results of Operations and F...

Press Release and Investing...

Regulation FD Disclosure

Subscription Agreement with...

Results of Operations and F...

Compliance with Nasdaq Bid ...

Reverse Stock Split

Common Share Purchase Agree...

Annual and Special Meeting ...

External Links:

Aptose Biosciences entered into a debt conversion agreement on March 18, 2025, converting $1,513,533.10 of debt into 409,063 shares at $3.70 each with Hanmi Pharmaceutical, along with an amended investor rights agreement.

AI Assistant

APTOSE BIOSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.